Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 6/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 10/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22470137 | 1.00 | KCNN4 (0.41) | KCNN4PDE2ANOTUMPTGER4P2RX7 | |
| SCHEMBL22470473 | 0.87 | F2 (0.38) | KCNN4PDE2ANOTUMPTGER4 | |
| SCHEMBL22470470 | 0.87 | F2 (0.38) | KCNN4PDE2ANOTUMPTGER4 | |
| SCHEMBL22470105 | 0.86 | ALDH1A1 (0.42) | KCNN4PDE2APTGER4 | |
| SCHEMBL29262043 | 0.86 | ALDH1A1 (0.42) | KCNN4PDE2APTGER4 | |
| SCHEMBL22470251 | 0.80 | KCNN4 (0.44) | KCNN4PDE2ANOTUMP2RX7 | |
| SCHEMBL22470247 | 0.80 | KCNN4 (0.44) | KCNN4PDE2ANOTUMP2RX7 | |
| SCHEMBL22470528 | 0.78 | PDE2A (0.48) | KCNN4PDE2ANOTUM | |
| SCHEMBL22470141 | 0.76 | KCNN4 (0.49) | KCNN4PDE2ANOTUM | |
| SCHEMBL22470069 | 0.76 | KCNN4 (0.49) | KCNN4PDE2ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006289-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2024-06-11 | — | — | US | disclosed |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-06-02 | — | — | US | disclosed |
| EP-3941903-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2022-01-26 | — | — | EP | disclosed |
| CN-113631538-A | Novel potassium channel inhibitors | 萨尼奥纳有限责任公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2020193419-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885PDE2A 730/4885NOTUM 4389/4885 |
| US-12006289-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885PDE2A 999/4885NOTUM 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.